Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease
09 mai 2022 07h00 HE
|
Athira Pharma, Inc.
– Study duration increased from 6 months to 18 months of open label treatment with fosgonimeton – BOTHELL, Wash., May 09, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late...
THE DAVOS ALZHEIMER’S COLLABORATIVE LAUNCHES INNOVATIVE EARLY DETECTION EFFORT
03 mai 2022 11h43 HE
|
Davos Alzheimer's Collaborative
New York, NY, May 03, 2022 (GLOBE NEWSWIRE) -- Unique global collaboration to prepare health systems for a future with new Alzheimer’s treatmentsPioneering use of blood-based biomarkers with...
IBN (InvestorBrandNetwork) Coverage Initiated for Silo Pharma Inc.
30 mars 2022 08h30 HE
|
Silo Pharma Inc.
NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with...
Athira Pharma Presents Study Overview and Baseline Data from ACT-AD Phase 2 Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease at the 2022 AD/PD™ Congress
20 mars 2022 04h50 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., March 20, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
Athira Pharma to Present Overview and Update from ACT-AD Phase 2 Trial of Fosgonimeton (ATH-1017) in Mild-to-Moderate Alzheimer’s Disease at AD/PD™ 2022 Congress
14 mars 2022 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., March 14, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
ProMIS Neurosciences to Present at the 2022 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PDTM) and Related Neurological Disorders
10 mars 2022 07h00 HE
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
Athira Pharma to Present Preclinical Data at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting
22 févr. 2022 07h05 HE
|
Athira Pharma, Inc.
Oral presentation on neurotrophic and procognitive properties of the active metabolite of fosgonimeton in preclinical models First presentation of preclinical data from ATH-1020 candidate for...
Athira Pharma Announces Publication of Phase 1 Results for Fosgonimeton (ATH-1017) in The Journal of Alzheimer's Disease
22 févr. 2022 07h00 HE
|
Athira Pharma, Inc.
Fosgonimeton demonstrated a statistically significant improvement of Event-Related Potential (ERP) P300 latency as compared with placebo in Alzheimer’s disease patients Fosgonimeton was...
National Down Syndrome Organizations Launch Joint Effort To Change CMS Proposal Concerning Coverage For New Class Of Alzheimer’s Treatments
04 févr. 2022 10h47 HE
|
National Down Syndrome Society
Atlanta, GA., Bismarck, ND., Burlington, MA., Denver, CO., Hoffman Estates, IL, NY, NY, Rockport, ME, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Down Syndrome Affiliates in Action (DSAIA), GiGi’s Playhouse...
CenExel Clinical Research Acquires California Neuroscience Research
10 janv. 2022 13h10 HE
|
CenExel Clinical Research
Salt Lake City, Utah, Jan. 10, 2022 (GLOBE NEWSWIRE) -- CenExel Clinical Research, Inc., (“CenExel”) announces the acquisition of California Neuroscience Research (“CenExel CNR”), a clinical...